Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 Aclaris Therapeutics (NASDAQ: ACRS) presented Phase 2a ePoster results for oral ATI-2138 at the 2026 AAD meeting showing rapid, sustained improvements in atopic dermatitis measures at week 12.Key week-12 outcomes for 10 mg BID included EASI -77%, BSA -70%, PP-NRS -50%, POEM -55%, and DLQI -65%, plus near-complete ITK occupancy and multi-pathway modulation.

#ACRS Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

www.stocktitan.net/news/ACRS/results-presen...

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting Aclaris Therapeutics (NASDAQ: ACRS) announced an ePoster presenting previously unreported results from its open-label Phase 2a trial of ATI-2138 for moderate-to-severe atopic dermatitis at the 2026 AAD Annual Meeting in Denver, CO on March 20, 2026.ATI-2138 is described as an investigational oral covalent inhibitor targeting ITK and JAK3. The poster lists Aclaris and Mount Sinai authors and will be available electronically during the meeting.

#ACRS Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

www.stocktitan.net/news/ACRS/aclaris-therap...

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it

#ACRS Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

www.stocktitan.net/news/ACRS/aclaris-therap...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic

#ACRS Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ACRS/aclaris-therap...

The February 2026 edition of the ACRS - JOURNAL OF ROAD SAFETY (Vol 37, Issue 1) is out now.
New research on climate impacts, vulnerable road users, crash injury prediction, and urban road safety.

Read it here: https://journalofroadsafety.org/

#RoadSafety #RoadTrauma #ACRS #JRS

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) Aclaris Therapeutics (NASDAQ: ACRS) reported preclinical results showing its oral ITK/JAK3 inhibitor ATI-2138 produced rapid, near-complete, and sustained hair regrowth in a validated murine reversal model of alopecia universalis versus control and ritlecitinib.At 300 ppm in chow, mean hair regrowth was 37% at week 2, 87% at week 4, and 93% at week 6 for ATI-2138 versus 25%, 48%, and 78% respectively for ritlecitinib. ATI-2138 is highly selective for ITK and JAK3 (>1,000-fold versus other JAKs). Aclaris expects to initiate a Phase 2b trial in H1 2026.

#ACRS Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

www.stocktitan.net/news/ACRS/aclaris-therap...

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept

#ACRS Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

www.stocktitan.net/news/ACRS/aclaris-therap...

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Extended Dosing of up to Every Three Months - - Initiation of Phase 1b Proof-of-Concept (POC) Trials in

#ACRS Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

www.stocktitan.net/news/ACRS/aclaris-therap...

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) Aclaris Therapeutics (NASDAQ: ACRS) was added to the Nasdaq Biotechnology Index (NBI), effective at the close of trading on December 19, 2025. The NBI tracks securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and uses a modified capitalization-weighted methodology.The company met NBI eligibility requirements, including minimum market capitalization, average daily trading volume and public company seasoning; the index is evaluated annually each December.

#ACRS Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

www.stocktitan.net/news/ACRS/aclaris-therap...

⚠️ New in the JRS: Research from Khon Kaen, Thailand shows how spatial road network characteristics can predict crash and injury hotspots, providing evidence to support safer urban street design.
🔗 https://doi.org/10.33492/JRS-D-25-4-2707507 #JRS #ACRS #RoadSafety #Thailand

⚠️ New in the Journal of Road Safety: Traffic calming, better lighting & safe crossings significantly reduce pedestrian harm, yet many cities struggle to implement them.
Read more ⬇️
https://doi.org/10.33492/JRS-D-25-4-2707507
#JRS #ACRS #RoadSafety #Pedestrians

⚠️ New in #JRS (36/4):
Gen-Z riders benefit from a digital safety boost.
The DINA HALO SAFETY model - short, interactive videos on social platforms - significantly improved motorcycle safety knowledge and safer-riding intentions.
🔗 https://doi.org/10.33492/JRS-D-25-4-2685822
#ACRS #RoadSafety

⚠️ NEW RESEARCH in JRS (36/4):
A study from Thailand’s Eastern Economic Corridor identifies the indicators needed to strengthen post-crash coordination, emergency care & data integration.
🔗 https://doi.org/10.33492/JRS-D-25-4-2658024
#JRS #ACRS #RoadSafety #PostCrashCare #Thailand

JOURNAL OF ROAD SAFETY - 36/4- OUT NOW

UNDERSTANDING VRU RISK PATTERNS ACROSS GERMANY
How spatial and demographic factors influence vulnerable road user crash frequencies, offering clear guidance for targeted safety initiatives.
https://journalofroadsafety.org
#JRS #ACRS #VRU #Germany

NEW ACRS – JRS - Vol.36/4
What hidden road features make crashes more likely?
New study on Indonesian toll roads available now in JRS.
READ ARTICLE HERE: https://doi.org/10.33492/JRS-D-25-4-2120803
#JRS #RoadSafety #TollRoads #Research #CrashPrevention #Indonesia #ACRS #SafeSystem

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of Phase 2 Trial in an Additional Indication Expected in the First Half of 2026 - -

#ACRS Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ACRS/aclaris-therap...

ACRS Revives Free Legal Clinics for Immigrant and Refugee Families in the South End After a pandemic pause, ACRS is once again connecting South End immigrant and refugee residents with free legal support — bridging language and access gaps in the justice system.

Free legal help has returned to the South End. ACRS is hosting monthly legal clinics for low-income immigrant and refugee families through December, offering pro bono advice on immigration, family, and employment law.

Maya Tizon (@mayatizon) reports here: soseaem.org/4oqkuRm #SeattleNews #ACRS

THANK YOU to everyone who joined us at #2025ARSC in Perth!
From inspiring talks to the Gala Dinner at Optus Stadium and the Road Safety Field Day at UWA, it was an unforgettable week of learning and collaboration.
👉 https://australasianroadsafetyconference.com.au/
#RoadSafety #ACRS #VisionZero

🟣 🌟 DAY THREE AT #2025ARSC 🌟 🟣
Today opens with Dr Lee Randall with “Road Safety Apartheid and the Imperative of Equity.”
Austroads plenary this afternoon: “Strengthening Road Safety Management for a Path to Zero.”
https://australasianroadsafetyconference.com.au/
#RoadSafety #PathToZero #ACRS

AFTERNOON SESSIONS AT #2025ARSC include: Local Government, E-scooters, Enforcement & Policing, Fatigue, Motorcyclists, Technology, Road Design, and Crash Data.
Plenary debate: “That we are on track to meet 2030 targets”
#ACRS Gala Dinner and Road Safety Awards
#RoadSafety #VisionZero #SafeRoads

🟣 🌟 Day Two of the 2025 Australasian Road Safety Conference begins in Perth! ☀️ 🟣
At 9am, we open with key addresses from ACRS and Austroads leaders, followed by keynote speaker Prof Wes Marshall, author of Killed by a Traffic Engineer.
#2025ARSC #RoadSafety #ACRS #Perth

🎉 2025 ARSC STARTS TODAY! 🎉
🗓️ 20-23 Oct
📍 Pan Pacific Perth
Theme: Equity, Elasticity & Evolution - advancing fairness, adaptability & innovation in road safety.
Join researchers, practitioners & policymakers from across Australasia.
#2025ARSC #RoadSafety #2025Perth #ACRS

The countdown is on with just 2 weeks until the 2025 Australasian Road Safety Conference!

From 20 - 23 October in Perth, ARSC brings together the brightest minds in road safety and injury prevention.

👉 Register now: australasianroadsafetyconference.com.au/registration/

#RoadSafety #ACRS

Top 3 Risks of a Poorly Created VPAT - TPGi Learn how a poorly created VPAT can cost contracts, create compliance risks, and damage buyer trust.

Learn how a poorly created VPAT can cost contracts, create compliance risks, and damage buyer trust.

www.tpgi.com/top-3-risks-...

#VPATs #ACRs #Compliance #DigitalAccessibility #Accessibility #A11y

2025 ARSC – Program Now Available! 🌟
Less than 8 weeks until #ARSC2025 in Perth.

👉 Inspiring plenaries
👉 Hands-on workshops
👉 Equity-focused talks
👉 Networking across the road safety sector.

📅 20–23 October | Perth, WA
📖 View the program: australasianroadsafetyconference.com.au/program/

#ACRS

2025 ACRS Excellence in Road Safety Award Taster Webinar

Thursday 25 September 2025 | 🕛 12–1:30pm (AEST)
Zoom | Free for members, $20 for non-members

👉 Register here: acrs.org.au/event/2025-a...

#RoadSafety #ACRS #Webinar #ExcellenceinRoadSafety #Awards

@creacher.bsky.social
Check it out!
#STEM
#ACRS
#Science

Join us in Perth for #ARSC2025 - 20-23 Oct.
Theme: Equity, Elasticity & Evolution. Four days of collaboration, innovation, and networking to make our roads safer.
Register now 👉 australasianroadsafetyconference.com.au/registration/
#RoadSafety #ARSC2025 #ACRS #VisionZero

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Aclaris Therapeutics (NASDAQ:ACRS) reported Q2 2025 financial results and provided significant pipeline updates. The company achieved positive results in its Phase 2a trial of ATI-2138, their ITK/JAK3 inhibitor for atopic dermatitis, demonstrating strong efficacy and tolerability. Additionally, Aclaris initiated dosing in two key trials: a Phase 2 trial of bosakitug (anti-TSLP antibody) and a Phase 1a/1b program for ATI-052 (anti-TSLP/IL-4R bispecific antibody).Financially, Aclaris reported a net loss of $15.4 million in Q2 2025, with cash reserves of $180.9 million as of June 30, 2025. The company expects its current cash position to fund operations into the second half of 2028. R&D expenses increased to $11.4 million, primarily due to expanded clinical development activities.

#ACRS Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ACRS/aclaris-therap...

COMING SOON!!

The AUGUST edition of the ACRS Journal of Road Safety (Vol 36, Issue 3) is out Wed 20 August here: journalofroadsafety.org

Featuring new research and case studies -
#ACRS #JRS #RoadSafety #OriginalRoadSafetyResearch #RoadSafetyCaseStudies